Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
5.63
USD
|
-3.43%
|
|
+0.18%
|
-44.42%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,502
|
4,335
|
1,796
|
596.6
|
827.4
|
463
|
-
|
-
|
Enterprise Value (EV)
1 |
1,045
|
3,932
|
1,296
|
159.2
|
400.2
|
231.2
|
367.9
|
376.3
|
P/E ratio
|
-11
x
|
-35.4
x
|
-9.32
x
|
-2.76
x
|
-5.01
x
|
-2.14
x
|
-2.2
x
|
-2.26
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
73.1
x
|
47.8
x
|
70.3
x
|
30.3
x
|
10.6
x
|
16.1
x
|
18.6
x
|
7.44
x
|
EV / Revenue
|
50.9
x
|
43.3
x
|
50.7
x
|
8.08
x
|
5.12
x
|
8.03
x
|
14.8
x
|
6.05
x
|
EV / EBITDA
|
-7.56
x
|
-30
x
|
-6.89
x
|
-0.72
x
|
-2.45
x
|
-0.95
x
|
-1.45
x
|
-1.42
x
|
EV / FCF
|
-18.6
x
|
-21
x
|
-7.55
x
|
-0.88
x
|
-2.92
x
|
-1.47
x
|
-1.49
x
|
-1.4
x
|
FCF Yield
|
-5.38%
|
-4.76%
|
-13.3%
|
-114%
|
-34.2%
|
-68.2%
|
-67.2%
|
-71.5%
|
Price to Book
|
6.16
x
|
11.1
x
|
3.28
x
|
1.69
x
|
2.2
x
|
2.23
x
|
6.78
x
|
5.8
x
|
Nbr of stocks (in thousands)
|
50,716
|
61,824
|
67,648
|
67,259
|
81,674
|
82,238
|
-
|
-
|
Reference price
2 |
29.61
|
70.11
|
26.55
|
8.870
|
10.13
|
5.630
|
5.630
|
5.630
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/22/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.53
|
90.73
|
25.54
|
19.71
|
78.12
|
28.8
|
24.83
|
62.22
|
EBITDA
1 |
-138.1
|
-130.9
|
-188.1
|
-219.6
|
-163.1
|
-243.9
|
-254.1
|
-265
|
EBIT
1 |
-140.9
|
-134.8
|
-193.1
|
-226
|
-169.2
|
-243.2
|
-263.6
|
-270.6
|
Operating Margin
|
-686.39%
|
-148.61%
|
-756.13%
|
-1,146.26%
|
-216.56%
|
-844.46%
|
-1,061.64%
|
-434.83%
|
Earnings before Tax (EBT)
1 |
-133.7
|
-116
|
-192.5
|
-220.4
|
-153.2
|
-220.2
|
-244.9
|
-245.7
|
Net income
1 |
-133.7
|
-116
|
-192.5
|
-220.4
|
-153.2
|
-222.6
|
-250.4
|
-261.4
|
Net margin
|
-651.43%
|
-127.82%
|
-753.61%
|
-1,118.26%
|
-196.13%
|
-772.86%
|
-1,008.73%
|
-420.11%
|
EPS
2 |
-2.680
|
-1.980
|
-2.850
|
-3.210
|
-2.020
|
-2.630
|
-2.562
|
-2.489
|
Free Cash Flow
1 |
-56.16
|
-187
|
-171.8
|
-181.5
|
-136.9
|
-157.6
|
-247.4
|
-269.2
|
FCF margin
|
-273.54%
|
-206.11%
|
-672.49%
|
-920.59%
|
-175.23%
|
-547.09%
|
-996.31%
|
-432.58%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/22/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
12.47
|
6.771
|
6.362
|
0.042
|
6.536
|
9.851
|
2.887
|
5.336
|
60.05
|
1.135
|
4.142
|
6.292
|
14.39
|
5.034
|
5.034
|
EBITDA
1 |
-40.1
|
-50.75
|
-
|
-
|
-61.87
|
-
|
-
|
-48.65
|
-22.5
|
-
|
-65.39
|
-66.62
|
-57.78
|
-
|
-
|
EBIT
1 |
-41.61
|
-50.75
|
-54.23
|
-57.52
|
-63.45
|
-50.96
|
-44.09
|
-50.16
|
-23.96
|
-66.99
|
-61.58
|
-60.49
|
-54.26
|
-63.24
|
-64.93
|
Operating Margin
|
-333.7%
|
-749.52%
|
-852.47%
|
-136,952.38%
|
-970.72%
|
-517.32%
|
-1,527.33%
|
-940.09%
|
-39.9%
|
-5,902.29%
|
-1,486.62%
|
-961.4%
|
-377.06%
|
-1,256.25%
|
-1,289.95%
|
Earnings before Tax (EBT)
1 |
-41.44
|
-50.52
|
-53.45
|
-55.73
|
-60.74
|
-49.04
|
-40.29
|
-45.02
|
-18.87
|
-61.95
|
-56.46
|
-55.16
|
-48.8
|
-60.27
|
-61.82
|
Net income
1 |
-41.44
|
-50.52
|
-53.45
|
-55.73
|
-60.74
|
-49.04
|
-40.29
|
-45.02
|
-18.87
|
-61.95
|
-56.38
|
-55.45
|
-48.91
|
-60.27
|
-61.82
|
Net margin
|
-332.31%
|
-746.05%
|
-840.19%
|
-132,680.95%
|
-929.28%
|
-497.78%
|
-1,395.57%
|
-843.68%
|
-31.43%
|
-5,458.15%
|
-1,361.24%
|
-881.26%
|
-339.89%
|
-1,197.36%
|
-1,228.11%
|
EPS
2 |
-0.6100
|
-0.7400
|
-0.7800
|
-0.8100
|
-0.8800
|
-0.7100
|
-0.5600
|
-0.5500
|
-0.2300
|
-0.7600
|
-0.6842
|
-0.6656
|
-0.5794
|
-0.6420
|
-0.6440
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/4/22
|
8/3/22
|
11/2/22
|
2/22/23
|
5/5/23
|
8/2/23
|
11/3/23
|
2/28/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
457
|
402
|
500
|
437
|
427
|
232
|
95.1
|
86.7
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-56.2
|
-187
|
-172
|
-181
|
-137
|
-158
|
-247
|
-269
|
ROE (net income / shareholders' equity)
|
-53.6%
|
-35.4%
|
-40.6%
|
-48.2%
|
-43.2%
|
-110%
|
-343%
|
-287%
|
ROA (Net income/ Total Assets)
|
-28.8%
|
-21.4%
|
-30.8%
|
-37%
|
-30.2%
|
-59.7%
|
-94.6%
|
-145%
|
Assets
1 |
464.6
|
540.7
|
625
|
595.9
|
506.7
|
373.2
|
264.6
|
180.4
|
Book Value Per Share
2 |
4.810
|
6.290
|
8.080
|
5.250
|
4.600
|
2.530
|
0.8300
|
0.9700
|
Cash Flow per Share
2 |
-
|
-
|
-2.420
|
-2.580
|
-1.790
|
-2.840
|
-2.860
|
-
|
Capex
1 |
6.17
|
7.16
|
7.98
|
4.12
|
4.72
|
5.25
|
5.25
|
5.67
|
Capex / Sales
|
30.04%
|
7.89%
|
31.23%
|
20.89%
|
6.04%
|
18.23%
|
21.15%
|
9.11%
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/22/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
5.63
USD Average target price
15.13
USD Spread / Average Target +168.80% Consensus |
1st Jan change
|
Capi.
|
---|
| -44.42% | 463M | | +67.53% | 63.85B | | -0.77% | 41.83B | | +45.66% | 40.65B | | -10.72% | 27.12B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +4.70% | 12.73B | | +24.10% | 12.11B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|